Meningococcal disease is a contagious bacterial disease caused by the bacteria Neisseria meningitidis (N meningitidis) with high fatality rates: up to 15% for infection of the central nervous system (meningitis) and up to 50% to 60% among patients with blood stream infection and shock; up to 15% of survivors are left with severe neurological deficits. People who have had close contact with someone who has a meningococcal infection and populations with known high carriage rates are offered antibiotics in order to eradicate the bacteria and thus prevent disease.
Data from 24 studies, most of high quality, including 6885 participants found that rifampin (also known as rifampicin), ciprofloxacin, ceftriaxone and penicillin are effective agents for eradicating carriage of N meningitidis. However, the use of rifampin may have a disadvantage as development of resistance to the antibiotic has been noted following treatment. Mild adverse events are associated with the different antibiotics used. Disease prevention could not be evaluated directly in this review as only data for eradication of the bacteria were available. Different follow-up periods were reported in the studies. Evidence in this review is current as of June 2013.
Vollständige Zusammenfassung lesen
Meningococcal disease is a contagious bacterial infection caused by Neisseria meningitidis (N meningitidis). Household contacts have the highest risk of contracting the disease during the first week of a case being detected. Prophylaxis is considered for close contacts of people with a meningococcal infection and populations with known high carriage rates.
Zielsetzungen
To study the effectiveness, adverse events and development of drug resistance of different antibiotics as prophylactic treatment regimens for meningococcal infection.
Suchstrategie
We searched CENTRAL 2013, Issue 6, MEDLINE (January 1966 to June week 1, 2013), Embase (1980 to June 2013) and LILACS (1982 to June 2013).
Auswahlkriterien
Randomised controlled trials (RCTs) or quasi-RCTs addressing the effectiveness of different antibiotics for: (a) prophylaxis against meningococcal disease; (b) eradication of N meningitidis.
Datensammlung und ‐analyse
Two review authors independently appraised the quality and extracted data from the included trials. We analysed dichotomous data by calculating the risk ratio (RR) and 95% confidence interval (CI) for each trial.
Hauptergebnisse
No new trials were found for inclusion in this update. We included 24 studies; 19 including 2531 randomised participants and five including 4354 cluster-randomised participants. There were no cases of meningococcal disease during follow-up in the trials, thus effectiveness regarding prevention of future disease cannot be directly assessed.
Mortality that was reported in one study was not related to meningococcal disease or treatment. Ciprofloxacin (RR 0.04; 95% CI 0.01 to 0.12), rifampin (rifampicin) (RR 0.17; 95% CI 0.13 to 0.24), minocycline (RR 0.28; 95% CI 0.21 to 0.37) and penicillin (RR 0.47; 95% CI 0.24 to 0.94) proved effective at eradicating N meningitidis one week after treatment when compared with placebo. Rifampin (RR 0.20; 95% CI 0.14 to 0.29), ciprofloxacin (RR 0.03; 95% CI 0.00 to 0.42) and penicillin (RR 0.63; 95% CI 0.51 to 0.79) still proved effective at one to two weeks. Rifampin was effective compared to placebo up to four weeks after treatment but resistant isolates were seen following prophylactic treatment. No trials evaluated ceftriaxone against placebo but rifampin was less effective than ceftriaxone after one to two weeks of follow-up (RR 5.93; 95% CI 1.22 to 28.68). Mild adverse events associated with treatment were observed.
Schlussfolgerungen der Autoren
Using rifampin during an outbreak may lead to the circulation of resistant isolates. Use of ciprofloxacin, ceftriaxone or penicillin should be considered. All four agents were effective for up to two weeks follow-up, though more trials comparing the effectiveness of these agents for eradicating N. meningitidis would provide important insights.
